文献速递临床试验与 GCP新药、器械与细胞基因治疗研发医学人工智能与信息学

基于听觉神经调控的处方数字疗法治疗失眠:SERENE随机对照试验方案

Auditory neuromodulation-based prescription digital therapeutic for insomnia disorder: study protocol for a randomized controlled trial (SERENE).
PubMed 文献 · Trials · 2026-07-09

SERENE是一项多中心、前瞻性、随机、双盲、假对照、优效性试验,在韩国6个中心纳入至少114例19-75岁ICD-10失眠且ISI≥15的成人,1:1随机接受BELL-001或假设备,主要终点为基线至4周ISI变化。BELL-001通过实时生物信号响应声反馈诱导自主神经下调,靶向失眠高唤醒机制。

要点

  • BELL-001为听觉神经调控处方数字疗法,靶向失眠高唤醒核心病理生理特征。
  • 主要终点为基线至4周ISI评分变化,采用假对照双盲优效性设计。
  • 纳入标准为ICD-10失眠诊断(F51.0或G47.0)且ISI≥15的19-75岁成人。

核心结论

  • SERENE试验将评估基于听觉神经调控的处方数字疗法BELL-001能否为失眠障碍患者提供有临床意义的改善。
  • 若证实有效且安全,本研究可能支持神经调控数字疗法作为失眠障碍的附加治疗选择。

研究设计与样本

  • 多中心、前瞻性、随机、双盲、假对照、优效性试验。
  • 从韩国6个临床中心纳入至少114例19-75岁ICD-10失眠(F51.0或G47.0)且ISI≥15的成人。
  • 合格参与者按1:1随机分配至BELL-001治疗组或假设备对照组。
  • 主要终点为基线至4周ISI评分变化。

关键数值与推荐

  • 主要终点:基线至4周失眠严重指数(ISI)评分变化。
  • 次要终点包括应答率(ISI降低≥6分)、睡眠日记主观入睡潜伏期和入睡后觉醒时间,以及评估嗜睡、疲劳、抑郁、焦虑、生活质量和工作效率的验证问卷。
  • 安全性分析评估治疗中出现的不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insomnia affects 10-15% of adults worldwide, significantly impairing quality of life, cognitive function, and work productivity. Current treatments present fundamental trade-offs: cognitive behavioral therapy for insomnia (CBT-I) demonstrates sustained efficacy but requires a prolonged treatment period, specialized therapists, and high patient engagement, while pharmacotherapy provides rapid relief but carries risks of dependence and cognitive impairment that limit long-term use. Existing prescription digital therapeutics (PDTs) address CBT-I's accessibility barriers but inherit its delayed therapeutic onset and adherence challenges. BELL-001 is an auditory neuromodulation-based PDT designed to induce autonomic downregulation through real-time biosignal-responsive acoustic feedback, targeting hyperarousal as a core pathophysiological feature of insomnia. METHODS: This is a multicenter, prospective, randomized, double-blind, sham-controlled, superiority trial designed to evaluate the efficacy and safety of BELL-001 in adults with insomnia. A minimum of 114 participants aged 19-75 years diagnosed with insomnia according to ICD-10 criteria (F51.0 or G47.0) and with an Insomnia Severity Index (ISI) score ≥ 15 will be enrolled from six clinical sites in the Republic of Korea. Eligible participants will be randomly assigned in a 1:1 ratio to either the treatment group using BELL-001 or the control group using a sham device. The primary endpoint is the change in ISI score from baseline to 4 weeks. Secondary endpoints include the response rate (ISI reduction ≥ 6 points), subjective sleep onset latency and wake after sleep onset from sleep diaries, and validated questionnaires assessing sleepiness, fatigue, depression, anxiety, quality of life, and work productivity. Treatment-emergent adverse events will be evaluated for safety analysis. DISCUSSION: The SERENE trial will evaluate whether an auditory neuromodulation-based PDT can provide clinically meaningful improvements. If efficacy and safety are demonstrated, this study may support the potential of neuromodulation-based digital therapeutics as an additional treatment option for patients with insomnia disorder. TRIAL REGISTRATION {4}: ClinicalTrials.gov (NCT07295431). Registered on 22 December 2025. https://clinicaltrials.gov/study/NCT07295431.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kim K, Kim H, Kim H, et al. Auditory neuromodulation-based prescription digital therapeutic for insomnia disorder: study protocol for a randomized controlled trial (SERENE). Trials. 2026. PMID: 42426835. doi:10.1186/s13063-026-09880-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。